The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease

NCT ID: NCT03444428

Last Updated: 2021-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-21

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach review will be approached for participation in the study
* Physiological assessment and measurement of arterial stiffness will be performed in all patients at baseline and after the use of non invasive ventilation for 6 weeks.
* MND patients not requiring mechanical ventilation will serve as controls since non invasive ventilation cannot be withheld from MND patients in type II respiratory failure.
* Data will be analysed to look for differences between groups, relationships in baseline or change from baseline in respiratory physiological measures, inflammatory indices, breathlessness, and arterial stiffness.

* Age, Height, Weight
* History and Physical Examination
* Evaluation of dysponea: mMRC, Borg Scale (Seated-Supine)
* Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
* Sleep Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
* 24 hour blood pressure monitor
* Carotid-femoral pulse wave velocity
* Respiratory Muscle Strength - Maximal Inspiratory Pressure, Maximal Expiratory Pressure, and Sniff Nasal Inspiratory Pressure
* Spirometry - FEV1 and FVC
* Arterial Blood Gas
* CRP and fibrinogen (clinically)
* Breathe CO exhale

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The stiffness of the arterial wall is highly relevant to cardiovascular disease. Large elastic arteries and smaller muscular conduit arteries become stiffer with ageing, a process that is accelerated in the presence of cardiovascular disease. Arterial stiffness increases also with various disease states, including hypertension, diabetes mellitus, obesity, smoking, hypercholesterolemia, and kidney disease. Numerous techniques have been developed to measure arterial stiffness, either in single vessels or in entire muscular arterial trees. These techniques have increasingly been shown to improve stratification of cardiovascular risk and risk reduction beyond that provided by conventional risk factors. Furthermore, large artery stiffness, measured via carotid-femoral pulse wave velocity, independently predicts the risk of cardiovascular events in both clinical and community-based cohorts.

Abnormalities in arterial stiffness have been noted in disorders characterized by hypoxia with or without hypercapnia. These abnormalities could be driven by the risk factors for those conditions (e.g. cigarette smoke, obesity). In COPD, all studies are consistent showing a significant increase in arterial stiffness compared with ex-smokers without airway obstruction and nonsmoker healthy control subjects. The severity of airway obstruction is consistently related to arterial stiffness in COPD. Furthermore, airflow limitation arising from cigarette smoking, but not airflow limitation in non-smokers, was associated with arterial stiffness in a general population independently of established risk factors. The presence of OSA was associated with higher arterial stiffness indices independent of major confounders. In this context, OSA is associated with increased arterial stiffness independent of blood pressure.

Non invasive ventilation has been shown to reduce arterial stiffness in obstructive sleep apnea. In particular, there are studies that have examined the impact of continuous positive airway pressure (CPAP) on arterial stiffness (measured with pulse wave velocity) in OSA patients. Other studies have examined changes in arterial stiffness (measured with other than pulse wave velocity method) after treatment of OSA with CPAP. Furthermore, to the best of our knowledge no investigation exists on the impact of non invasive bilevel positive airway pressure ventilation on arterial stiffness in neuromuscular disease.

The Lane Fox Unit, the UK's largest weaning, rehabilitation and home ventilation unit, is treating neuromuscular patients. In neuromuscular disease, especially in MND, confounding factors as obesity, cigarette smoke, hypertension, and diabetes mellitus can be excluded. This gives the opportunity to determine whether hypoxemia and/or hypercapnia alone cause arterial stiffness. Furthermore, in this pilot study it will be investigated whether non invasive ventilation has any effect on arterial stiffness in MND patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Motor Neurone Disease Hypoxemia and/or Hypercapnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non Invasive Ventilation

* Age, height, weight
* History and Physical Examination
* Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)
* Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
* Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
* 24h Blood Pressure monitor
* Spirometry - FEV1 and FVC
* Respiratory muscle strength - MIP, MEP, and SNIP
* Arterial Blood Gases
* Carotid-femoral pulse wave velocity
* Breath CO exhale

Non Invasive Ventilation

Intervention Type OTHER

Assessments for those participants who are being set up onto NIV

Without Non Invasive Ventilation

Age, height, weight

* History and Physical Examination
* Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)
* Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
* Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
* 24h Blood Pressure monitor
* Spirometry - FEV1 and FVC
* Respiratory muscle strength - MIP, MEP, and SNIP
* Arterial Blood Gases
* Carotid-femoral pulse wave velocity
* Breath CO exhale

Without Non Invasive Ventilation

Intervention Type OTHER

Assessments for those participants who are not being set up onto NIV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non Invasive Ventilation

Assessments for those participants who are being set up onto NIV

Intervention Type OTHER

Without Non Invasive Ventilation

Assessments for those participants who are not being set up onto NIV

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MND diagnosis
* The ability to perform the respiratory function testing satisfactorily
* Stable clinical and functional state for at least four weeks before testing
* BMI 20-30 kg•m-2

Exclusion Criteria

* Pregnancy
* Aged \<18, \>80
* Significant physical or psychiatric comorbidity that would prevent compliance with trial protocol
* Unstable clinical state
* Use of mechanical ventilation
* Cardiovascular disorders (history, physical examination)
* Known lung disease, such as asthma or COPD or any other cause of hypoxemia and/or hypercapnia but MND (history, physical examination, CXR review \[High Resolution Computed Tomography if CXR is not compatible with neuromuscular disease alone\])
* Airway obstruction (FEV1/FVC\<0.75)
* Diabetes mellitus
* Obesity (BMI\>30 kg•m-2)
* Smoking history (\>10 pack∙years or active smoker)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Guy's and St Thomas' NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick Murphy

Role: PRINCIPAL_INVESTIGATOR

Guys and St Thomas NHS Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guys and St Thomas NHS Trust

London, , United Kingdom

Site Status

Royal Brompton and Harefield NHS Trust

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

210214 16/LO/1560

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.